The Central Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Septic Pathogen Lipid Transport and Clearance
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Central Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Septic Pathogen Lipid Transport and Clearance
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
Volume 192, Issue 11, Pages 1275-1286
Publisher
American Thoracic Society
Online
2015-08-08
DOI
10.1164/rccm.201505-0876ci
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effects of Niacin, Statin, and Fenofibrate on Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Levels in Patients With Dyslipidemia
- (2015) Amit V. Khera et al. AMERICAN JOURNAL OF CARDIOLOGY
- Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
- (2015) Frederick J Raal et al. LANCET
- PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
- (2015) Frederick J Raal et al. LANCET
- Reduction of Low-Density Lipoprotein Cholesterol by Monoclonal Antibody Inhibition of PCSK9
- (2014) Evan A. Stein et al. Annual Review of Medicine
- Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease
- (2014) Sha Li et al. ATHEROSCLEROSIS
- The effect of insulin on circulating PCSK9 in postmenopausal obese women
- (2014) Zuhier Awan et al. CLINICAL BIOCHEMISTRY
- Plasma proprotein convertase subtilisin–kexin type 9 is predominantly related to intermediate density lipoproteins
- (2014) Arjan J. Kwakernaak et al. CLINICAL BIOCHEMISTRY
- Low Preoperative Cholesterol Level Is a Risk Factor of Sepsis and Poor Clinical Outcome in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass*
- (2014) Laurent Lagrost et al. CRITICAL CARE MEDICINE
- Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials
- (2014) E. A. Stein et al. EUROPEAN HEART JOURNAL
- APOε4 is associated with enhanced in vivo innate immune responses in human subjects
- (2014) Stephen C. Gale et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease
- (2014) Yan Zhang et al. Journal of Clinical Lipidology
- Influence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects
- (2014) Jacqueline M. Anderson et al. Journal of Clinical Lipidology
- Murine Bactericidal/Permeability-Increasing Protein Inhibits the Endotoxic Activity of Lipopolysaccharide and Gram-Negative Bacteria
- (2014) I. Wittmann et al. JOURNAL OF IMMUNOLOGY
- Apolipoprotein E-Mediated Immune Regulation in Sepsis
- (2014) O. M. Kattan et al. JOURNAL OF IMMUNOLOGY
- Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans
- (2014) Ylva Bonde et al. JOURNAL OF LIPID RESEARCH
- Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)
- (2014) Frederick J. Raal et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Haplotype analysis of ApoAI gene and sepsis-associated acute lung injury
- (2014) Jian Hao et al. Lipids in Health and Disease
- A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
- (2014) Dirk J. Blom et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rosuvastatin for Sepsis-Associated Acute Respiratory Distress Syndrome
- (2014) NEW ENGLAND JOURNAL OF MEDICINE
- Plasma PCSK9 Levels Are Elevated with Acute Myocardial Infarction in Two Independent Retrospective Angiographic Studies
- (2014) Naif A. M. Almontashiri et al. PLoS One
- Bridging Lipid Metabolism and Innate Host Defense
- (2014) C. dos Santos et al. Science Translational Medicine
- PCSK9 is a critical regulator of the innate immune response and septic shock outcome
- (2014) K. R. Walley et al. Science Translational Medicine
- The EUPHRATES trial (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock): study protocol for a randomized controlled trial
- (2014) David J Klein et al. Trials
- Plasma PCSK9 in Nephrotic Syndrome and in Peritoneal Dialysis: A Cross-sectional Study
- (2013) Kyubok Jin et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Beyond LDL-C lowering: Distinct molecular sphingolipids are good indicators of proprotein convertase subtilisin/kexin type 9 (PCSK9) deficiency
- (2013) Minna T. Jänis et al. ATHEROSCLEROSIS
- Loss of Plasma Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) After Lipoprotein Apheresis
- (2013) Hagai Tavori et al. CIRCULATION RESEARCH
- Low-density lipoprotein cholesterol reduction by inhibition of PCSK9
- (2013) Evan A. Stein CURRENT OPINION IN LIPIDOLOGY
- Effect of Statin Therapy on Mortality in Patients With Ventilator-Associated Pneumonia
- (2013) Laurent Papazian JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation
- (2013) Tanja Kosenko et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Plasma PCSK9 Is a Late Biomarker of Severity in Patients With Severe Trauma Injury
- (2013) Maëlle Le Bras et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- PCSK9-mediated degradation of the LDL receptor generates a 17 kDa C-terminal LDL receptor fragment
- (2013) Kristian Tveten et al. JOURNAL OF LIPID RESEARCH
- Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
- (2013) Kevin Fitzgerald et al. LANCET
- Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations
- (2013) Janice Mayne et al. Lipids in Health and Disease
- Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome
- (2013) S. Liu et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets
- (2013) Bertrand Cariou et al. Nutrition & Metabolism
- Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia
- (2013) M.C.G.J. Brouwers et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Evidence from a Randomized Trial That Simvastatin, but Not Ezetimibe, Upregulates Circulating PCSK9 Levels
- (2013) Heiner K. Berthold et al. PLoS One
- Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)
- (2013) Maryssa Canuel et al. PLoS One
- Long-term effects of ezetimibe-plus-statin therapy on low-density lipoprotein cholesterol levels as compared with double-dose statin therapy in patients with coronary artery disease
- (2012) Kozo Okada et al. ATHEROSCLEROSIS
- The effect of rosuvastatin on incident pneumonia: results from the JUPITER trial
- (2012) V. Novack et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia
- (2012) Frederick Raal et al. CIRCULATION
- Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients
- (2012) David Sullivan et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Furin-cleaved Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Is Active and Modulates Low Density Lipoprotein Receptor and Serum Cholesterol Levels
- (2012) Michael T. Lipari et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia
- (2012) R. Huijgen et al. JOURNAL OF LIPID RESEARCH
- Effects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels
- (2012) Clapton S. Dias et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial
- (2012) Evan A Stein et al. LANCET
- Structural basis of transfer between lipoproteins by cholesteryl ester transfer protein
- (2012) Lei Zhang et al. Nature Chemical Biology
- Antibodies against PCSK9—a new era of therapy
- (2012) Alexandra King Nature Reviews Cardiology
- Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
- (2012) Evan A. Stein et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
- (2012) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia
- (2012) Eli M. Roth et al. NEW ENGLAND JOURNAL OF MEDICINE
- Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor–independent pathways
- (2012) Jamie Cameron et al. Translational Research
- Crosstalk between reverse cholesterol transport and innate immunity
- (2012) Kathleen M. Azzam et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Scavenger Receptor Class A Plays a Central Role in Mediating Mortality and the Development of the Pro-Inflammatory Phenotype in Polymicrobial Sepsis
- (2012) Tammy R. Ozment et al. PLoS Pathogens
- Endogenous Estrogens Lower Plasma PCSK9 and LDL Cholesterol But Not Lp(a) or Bile Acid Synthesis in Women
- (2011) Lena Persson et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study
- (2011) M.C.G.J. Brouwers et al. ATHEROSCLEROSIS
- Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes
- (2011) Bruno Vergès et al. ATHEROSCLEROSIS
- Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: Results from a crossover study
- (2011) Tohru Noguchi et al. ATHEROSCLEROSIS
- Plasma PLTP (phospholipid-transfer protein): an emerging role in ‘reverse lipopolysaccharide transport’ and innate immunity
- (2011) Thomas Gautier et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Bioinformatics of the TULIP domain superfamily: Figure 1
- (2011) Klaus O. Kopec et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Rosuvastatin, Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations, and LDL Cholesterol Response: the JUPITER Trial
- (2011) Z. Awan et al. CLINICAL CHEMISTRY
- Plasma proprotein convertase subtilisin kexin type 9 is a heritable trait of familial combined hyperlipidaemia
- (2011) Martijn C.G.J. Brouwers et al. CLINICAL SCIENCE
- Location, synthesis and function of glycolipids and polyglycerolphosphate lipoteichoic acid in Gram-positive bacteria of the phylum Firmicutes
- (2011) Nathalie T. Reichmann et al. FEMS MICROBIOLOGY LETTERS
- Association Between Statins Given in Hospital and Mortality in Pneumonia Patients
- (2011) Michael B. Rothberg et al. JOURNAL OF GENERAL INTERNAL MEDICINE
- Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9
- (2011) Brandon Ason et al. JOURNAL OF LIPID RESEARCH
- Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents
- (2011) Robert J Konrad et al. Lipids in Health and Disease
- Polymyxin B-Immobilized Fiber Column Hemoperfusion Therapy for Septic Shock
- (2011) Chieko Mitaka et al. SHOCK
- Continuation of Statin Therapy in Patients with Presumed Infection
- (2010) Peter S. Kruger et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Cholesterol Efflux Potential and Antiinflammatory Properties of High-Density Lipoprotein After Treatment With Niacin or Anacetrapib
- (2010) Laurent Yvan-Charvet et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients
- (2010) Bertrand Cariou et al. ATHEROSCLEROSIS
- Plasma PCSK9 is increased by Fenofibrate and Atorvastatin in a non-additive fashion in diabetic patients
- (2010) P. Costet et al. ATHEROSCLEROSIS
- Plasma proprotein convertase subtilisin–kexin type 9 does not change during 24h insulin infusion in healthy subjects and type 2 diabetic patients
- (2010) Paul J.W.H. Kappelle et al. ATHEROSCLEROSIS
- Candidate Gene Association Resource (CARe)
- (2010) Kiran Musunuru et al. Circulation-Cardiovascular Genetics
- Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients
- (2010) D. C. Chan et al. DIABETES OBESITY & METABOLISM
- The Apolipoprotein E-Mimetic Peptide COG112 Inhibits NF-κB Signaling, Proinflammatory Cytokine Expression, and Disease Activity in Murine Models of Colitis
- (2010) Kshipra Singh et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Statins protect against fulminant pneumococcal infection and cytolysin toxicity in a mouse model of sickle cell disease
- (2010) Jason W. Rosch et al. JOURNAL OF CLINICAL INVESTIGATION
- Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans
- (2010) Jeffrey D. Browning et al. JOURNAL OF LIPID RESEARCH
- High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol
- (2010) Greg Welder et al. JOURNAL OF LIPID RESEARCH
- Meta-analysis of Comparative Efficacy of Increasing Dose of Atorvastatin Versus Rosuvastatin Versus Simvastatin on Lowering Levels of Atherogenic Lipids (from VOYAGER)
- (2009) Stephen J. Nicholls et al. AMERICAN JOURNAL OF CARDIOLOGY
- Apolipoprotein A-I mimetic peptide treatment inhibits inflammatory responses and improves survival in septic rats
- (2009) Zhenghao Zhang et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- Atorvastatin increases expression of low-density lipoprotein receptor mRNA in human circulating mononuclear cells
- (2009) Anothai Pocathikorn et al. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
- Plasma Proprotein Convertase Subtilisin/Kexin Type 9: A Marker of LDL Apolipoprotein B-100 Catabolism?
- (2009) D. C. Chan et al. CLINICAL CHEMISTRY
- PCSK9 impedes hepatitis C virus infectionin vitroand modulates liver CD81 expression
- (2009) Patrick Labonté et al. HEPATOLOGY
- Early Use of Polymyxin B Hemoperfusion in Abdominal Septic Shock
- (2009) Dinna N. Cruz et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Hepatocyte Nuclear Factor 1α Plays a Critical Role inPCSK9Gene Transcription and Regulation by the Natural Hypocholesterolemic Compound Berberine
- (2009) Hai Li et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Genetic and Metabolic Determinants of Plasma PCSK9 Levels
- (2009) Susan G. Lakoski et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Assessment of cholesteryl ester transfer protein inhibitors for interaction with proteins involved in the immune response to infection
- (2009) Ronald W. Clark et al. JOURNAL OF LIPID RESEARCH
- Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants
- (2009) Sekar Kathiresan et al. NATURE GENETICS
- Inhibition of PCSK9: A powerful weapon for achieving ideal LDL cholesterol levels
- (2009) D. Steinberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Plasma PCSK9 Concentrations Correlate with LDL and Total Cholesterol in Diabetic Patients and Are Decreased by Fenofibrate Treatment
- (2008) G. Lambert et al. CLINICAL CHEMISTRY
- Molecular biology of inflammation and sepsis: A primer*
- (2008) Ismail Cinel et al. CRITICAL CARE MEDICINE
- Comparison of the immunostimulatory and proinflammatory activities of candidate Gram-positive endotoxins, lipoteichoic acid, peptidoglycan, and lipopeptides, in murine and human cells
- (2008) Matthew R. Kimbrell et al. IMMUNOLOGY LETTERS
- Effect of Plasma Phospholipid Transfer Protein Deficiency on Lethal Endotoxemia in Mice
- (2008) Thomas Gautier et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
- (2008) M. Frank-Kamenetsky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- HUMAN CHOLESTERYL ESTER TRANSFER PROTEIN EXPRESSION ENHANCES THE MOUSE SURVIVAL RATE IN AN EXPERIMENTAL SYSTEMIC INFLAMMATION MODEL
- (2008) Patrícia M. Cazita et al. SHOCK
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation